DeLisa Group featured in the journal PNAS and the Chronicle
Conjugate vaccines have proven to be an effective and safe strategy for reducing the incidence of disease caused by bacterial pathogens. However, the manufacture of these vaccines is technically demanding, inefficient, and expensive, thereby limiting their widespread use. To circumvent these issues, the DeLisa lab has developed an alternative methodology for generating glycoconjugate vaccines whereby recombinant polysaccharide biosynthesis is coordinated with vesicle formation in nonpathogenic Escherichia coli, resulting in glycosylated outer membrane vesicles (glycOMVs) that can effectively deliver pathogen-mimetic glycotopes to the immune system. An attractive feature of the approach is the fact that different plasmid-encoded polysaccharide biosynthetic pathways can be readily transformed into E. coli, enabling a “plug-and-play” platform for the on-demand creation of glycOMV vaccine candidates that carry heterologous glycotopes from numerous pathogenic bacteria. This work published online today in the journal Proceedings of the National Academy of Sciences along with a story in the Cornell Chronicle.
PNAS article: http://www.pnas.org/content/early/2016/06/01/1518311113.full
Chronicle News Story: http://www.news.cornell.edu/stories/2016/06/engineered-e-coli-vesicles-act-vaccine-deliverers